Dietary SupplementationNCT07404540
Effect of β-alanine Supplementation and Training on Ergogenic Measures and Plasma Metabolites in Untrained Young Adults
A study testing β-Alanine in people with Dietary Supplementation and Healthy Vollunteer, run by University of Pecs at 1 site in Hungary.
Trial summary
This study enrolled untrained young adults to evaluate the effects of β-alanine supplementation combined with a structured exercise training program. Participants were randomly assigned to receive either β-alanine or a placebo while completing a six-week training regimen. Read more about this study
- Who is it for?
- Ages 18 to 30 yearsHealthy volunteers can take part
- Conditions the study is for
- Dietary Supplementation, Healthy Vollunteer
- What is being tested?
- β-Alanine
- Type of treatment
- Pill or oral medicine
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 46 participants
- Where
- 1 siteHungary
- Study dates
- Jan 2012to Mar 2012
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 30 years
- All sexes
- Healthy volunteers accepted
- Adult
Who may be able to join
- Healthy young adults aged 18-30 years.
- Untrained individuals without participation in structured resistance or endurance training during the previous 6 months.
- Not physically inactive, but not engaged in regular structured exercise training.
- Ability to participate in a six-week supervised multicomponent exercise training program.
- Willingness to comply with study procedures, training sessions, and supplementation protocol.
- Provision of written informed consent.
Who cannot join
- Known cardiovascular, metabolic, neuromuscular, or musculoskeletal disease.
- Acute injury at the time of enrollment.
- Regular use of medications or dietary supplements affecting muscle metabolism or exercise performance.
- Participation in structured resistance or endurance training during the previous 6 months.
- Failure to comply with the study protocol or training requirements.
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Effect of β-alanine Supplementation and Training on Ergogenic Parameters and Plasma Metabolites in Untrained Young Adults: a Randomized, Placebo-controlled, Double-blind Trial
This study enrolled untrained young adults to evaluate the effects of β-alanine supplementation combined with a structured exercise training program. Participants were randomly assigned to receive either β-alanine or a placebo while completing a six-week training regimen. Before and after the intervention, physical performance tests and blood samples were collected to assess changes in performance measures and biochemical markers in the blood. The purpose of the study was to determine how β-alanine supplementation influences exercise performance and related physiological outcomes in individuals who had not previously engaged in regular training.
Read the detailed description
This randomized, double-blind, placebo-controlled study was conducted to evaluate the effects of β-alanine supplementation combined with a structured exercise training program in untrained young adults. Participants were randomly assigned to receive either β-alanine supplementation or a matching placebo while completing a six-week supervised training intervention. Both participants and investigators responsible for training supervision and outcome assessments were blinded to group allocation.
The primary outcome measures focused on changes in physical performance capacity. Maximal muscle strength was assessed using standardized dynamometric measurements, and aerobic capacity was evaluated using a validated shuttle run test performed before and after the intervention.
Secondary outcome measures included changes in anthropometric parameters, pulmonary function, and exercise-related metabolic responses. Blood lactate concentrations were measured during standardized exercise testing to characterize metabolic responses to training and supplementation. In addition, fasting venous blood samples were collected before and after the intervention to determine plasma concentrations of β-alanine, histidine, and carnosine as biochemical outcome measures related to supplementation and training adaptation.
All outcome measures were collected at baseline and following completion of the six-week intervention period. Adverse events were monitored throughout the study duration through participant self-report and investigator observation. All study procedures were performed in accordance with ethical approval and institutional guidelines.
- Conditions
- Dietary Supplementation, Healthy Vollunteer
- Being tested
- β-Alanine, Placebo
- Keywords
- β-alanine, Exercise training, Dietary supplementation, Physical performance, Untrained adults
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
β-AlanineDietary supplement
β-alanine was administered orally at a dose of 50 mg/kg/day, divided into multiple daily doses and consumed with meals, throughout the six-week training intervention.
PlaceboDietary supplement
Participants received visually identical placebo capsules following the same dosing schedule as the β-alanine group during the six-week training intervention.
| Study group | Role | What they receive |
|---|---|---|
| β-Alanine Supplementation | Experimental | Participants received β-alanine supplementation at a dose of 50 mg/kg/day, divided into multiple daily doses, in combination with a supervised six-week exercise training program. Receives: Dietary Supplement: β-Alanine |
| Placebo | Placebo comparator | Participants received a visually identical placebo following the same dosing schedule as the supplementation group, in combination with a supervised six-week exercise training program. Receives: Dietary Supplement: Placebo |
What is being measured
The primary outcome is the main question the study is designed to answer.
Change in maximal muscle strength
Maximal muscle strength was assessed by dynamometric measurements of maximal voluntary isometric contraction.
Measured: Baseline and 6 weeks
Change in aerobic capacity
Aerobic capacity was estimated by VO₂max derived from the 20-m multistage fitness test (shuttle run).
Measured: Baseline and 6 weeks
Secondary outcomes (7)
Body mass index (BMI)
Body mass index calculated from measured height and body mass..
Measured: Baseline and 6 weeks
Body fat percentage
Body fat percentage estimated from standardized skinfold thickness measurements.
Measured: Baseline and 6 weeks
Forced vital capacity (FVC)
Forced vital capacity measured by spirometry using a portable spirometer to assess respiratory function.
Measured: Baseline and 6 weeks
Acute blood lactate response to dynamometric exercise
Acute blood lactate responses were measured during standardized dynamometric exercise testing.
Measured: Baseline and 6 weeks
Plasma β-alanine concentration
Plasma β-alanine concentration measured from fasting venous blood samples.
Measured: Baseline and 6 weeks
Plasma histidine concentration
Plasma histidine concentration measured from fasting venous blood samples.
Measured: Baseline and 6 weeks
Plasma carnosine concentration
Plasma carnosine concentration measured from fasting venous blood samples.
Measured: Baseline and 6 weeks
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted11 Feb 2026
- Study startJan 2012
- Primary completionMar 2012
- Study completionMar 2012
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Dietary SupplementationStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Model description
- Participants were randomly assigned in a 1:1 ratio to receive either β-alanine supplementation or a matchin
- Masking
- Double blind
- Who is masked
- Participant, Investigator
- Enrolment
- 46 participants (actual)
Sponsor and investigators
- Lead sponsor
- University of Pecs
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, David Csala, University of Pecs
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07404540
- Sponsor's protocol ID
- 316-2406-1/KK15/2011
- Status last verified
- Jul 2026
- First submitted
- 29 Jan 2026
- Last updated
- 22 Jul 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No: Individual participant data will not be shared publicly due to data protection and privacy considerations. De-identified data may be made available upon reasonable request to the corresponding author, subject to institutional approval.
Study at a glance
From the registry record, last updated by the sponsor on 22 Jul 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Effect of β-alanine Supplementation and Training on Ergogenic Parameters and Plasma Metabolites in Untrained Young Adults: a Randomized, Placebo-controlled, Double-blind Trial
- ClinicalTrials.gov ID
- NCT07404540
- Acronym / sponsor ID
- 316-2406-1/KK15/2011
- Conditions
- Dietary Supplementation, Healthy Vollunteer
- Keywords
- β-alanine, Exercise training, Dietary supplementation, Physical performance, Untrained adults
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 46 participants (actual)
- Lead sponsor
- University of PecsUniversity, hospital or other
- Study start
- Jan 2012 (actual)
- Primary completion
- Mar 2012 (actual)
- Study completion
- Mar 2012 (actual)
- First posted
- 11 Feb 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This study enrolled untrained young adults to evaluate the effects of β-alanine supplementation combined with a structured exercise training program. Participants were randomly assigned to receive either β-alanine or a placebo while completing a six-week training regimen. Before and after the intervention, physical performance tests and blood samples were collected to assess changes in performance measures and biochemical markers in the blood. The purpose of the study was to determine how β-alanine supplementation influences exercise performance and related physiological outcomes in individuals who had not previously engaged in regular training.
Detailed description
This randomized, double-blind, placebo-controlled study was conducted to evaluate the effects of β-alanine supplementation combined with a structured exercise training program in untrained young adults. Participants were randomly assigned to receive either β-alanine supplementation or a matching placebo while completing a six-week supervised training intervention. Both participants and investigators responsible for training supervision and outcome assessments were blinded to group allocation.
The primary outcome measures focused on changes in physical performance capacity. Maximal muscle strength was assessed using standardized dynamometric measurements, and aerobic capacity was evaluated using a validated shuttle run test performed before and after the intervention.
Secondary outcome measures included changes in anthropometric parameters, pulmonary function, and exercise-related metabolic responses. Blood lactate concentrations were measured during standardized exercise testing to characterize metabolic responses to training and supplementation. In addition, fasting venous blood samples were collected before and after the intervention to determine plasma concentrations of β-alanine, histidine, and carnosine as biochemical outcome measures related to supplementation and training adaptation.
All outcome measures were collected at baseline and following completion of the six-week intervention period. Adverse events were monitored throughout the study duration through participant self-report and investigator observation. All study procedures were performed in accordance with ethical approval and institutional guidelines.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind (participant, investigator)
- Number of arms
- 2
- Model description
- Participants were randomly assigned in a 1:1 ratio to receive either β-alanine supplementation or a matchin
| Arm | Type | Receives |
|---|---|---|
| β-Alanine Supplementation | Experimental | Dietary Supplement: β-AlanineParticipants received β-alanine supplementation at a dose of 50 mg/kg/day, divided into multiple daily doses, in combination with a supervised six-week exercise training program. |
| Placebo | Placebo comparator | Dietary Supplement: PlaceboParticipants received a visually identical placebo following the same dosing schedule as the supplementation group, in combination with a supervised six-week exercise training program. |
Who may qualify
- Ages
- 18 to 30 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult
Key inclusion criteria (6 listed)
- Healthy young adults aged 18-30 years.
- Untrained individuals without participation in structured resistance or endurance training during the previous 6 months.
- Not physically inactive, but not engaged in regular structured exercise training.
- Ability to participate in a six-week supervised multicomponent exercise training program.
- Willingness to comply with study procedures, training sessions, and supplementation protocol.
Key exclusion criteria (5 listed)
- Known cardiovascular, metabolic, neuromuscular, or musculoskeletal disease.
- Acute injury at the time of enrollment.
- Regular use of medications or dietary supplements affecting muscle metabolism or exercise performance.
- Participation in structured resistance or endurance training during the previous 6 months.
- Failure to comply with the study protocol or training requirements.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| β-Alanineβ-alanine was administered orally at a dose of 50 mg/kg/day, divided into multiple daily doses and consumed with meals, throughout the six-week training intervention. | Dietary supplement | β-Alanine Supplementation |
| PlaceboParticipants received visually identical placebo capsules following the same dosing schedule as the β-alanine group during the six-week training intervention. | Dietary supplement | Placebo |
Primary outcome
Change in maximal muscle strength
Time frame: Baseline and 6 weeks
Maximal muscle strength was assessed by dynamometric measurements of maximal voluntary isometric contraction.
Change in aerobic capacity
Time frame: Baseline and 6 weeks
Aerobic capacity was estimated by VO₂max derived from the 20-m multistage fitness test (shuttle run).
7 secondary outcomes
Body mass index (BMI)
Time frame: Baseline and 6 weeks
Body fat percentage
Time frame: Baseline and 6 weeks
Forced vital capacity (FVC)
Time frame: Baseline and 6 weeks
Acute blood lactate response to dynamometric exercise
Time frame: Baseline and 6 weeks
Plasma β-alanine concentration
Time frame: Baseline and 6 weeks
Plasma histidine concentration
Time frame: Baseline and 6 weeks
Plasma carnosine concentration
Time frame: Baseline and 6 weeks
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 22 Jul 2026.
- Individual participant dataSharing planned: No. Individual participant data will not be shared publicly due to data protection and privacy considerations. De-identified data may be made available upon reasonable request to the corresponding author, subject to institutional approval.
Related trials for Dietary Supplementation
Recruiting
Micronutrient Supplementation and Chronotherapy in Children With ADHD
Attention Deficit Hyperactivity Disorder (ADHD)
Recruiting
Effects of Red Panax Ginseng Supplementation on Cognitive Performance and Emotional Well-Being in Young Healthy Adults
Mental Acuity
Not yet recruiting
Efficacy of Carnitine Complex in Improving Hepatic Steatosis in Potential Liver Donors
Hepatic Steatosis, Fatty Liver
RecruitingPhase 2
FAST for DM - Fatty Acid Supplementation Trial (FAST) for Dermatomyositis (DM)
Dermatomyositis (DM), Juvenile Dermatomyositis (JDM)
Enrolling by invitation
Effect of Omega-3 Supplementation on Pregnant Outcomes and Inflammation Markers of Women Infected With HIV Using Antiretroviral Therapy
Pregnant HIV Positive Women
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing β-Alanine in people with Dietary Supplementation and Healthy Vollunteer, run by University of Pecs at 1 site in Hungary.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 6 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 22 Jul 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Hungary. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Change in maximal muscle strength (time frame: Baseline and 6 weeks). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 22 Jul 2026.